INNOVATION ARTICLES
-
The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future
The American Diabetes Association 2026 conference showed where we are and where we're going with GLP-1 therapies.
-
2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio
Dr. Chat Jayasuriya discusses EnkaBio’s meniscus repair therapy, fundraising, Nucleate’s impact, CEO search, and tech transfer from Brown/Rhode Island Hospital.
-
2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics
Chris Clifford, founder of Mimic Therapeutics, describes the company’s mission as protecting cell therapies from immune rejection, with an initial focus on Type 1 diabetes.
-
Strategic Synthesis Of ASGCT And ASCO 2026
The spring 2026 conference season made one thing obvious to those of us watching the data: the artisan era of ex vivo cellular manufacturing is finally receding.
-
2026 Nucleate Boston Activator Cohort Interview: Michael Cronce — Omni Therapeutics
Omni Therapeutics is developing first-in-class nucleotides from a novel immune metabolite, using Nucleate support to advance colorectal cancer programs.
-
A New De Novo Protein Design Platform For GPCR Drug Discovery
Skape Bio and UW created an AI-driven platform to design miniproteins that modulate GPCRs in living cells, opening new paths for biologic drug discovery.
INNOVATION ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS
-
Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.
-
Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.
-
In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.
-
Well-designed lipid nanoparticles enable safe, efficient delivery. OVA-based models show how formulation choices shape efficacy, safety, and anti-tumor outcomes in melanoma research.
-
New drug modalities are transforming treatment but bring new challenges. See how hybrid approaches that combine biologics and chemistry are redefining the design of innovative therapies.
-
Learn how these high-affinity, epitope-diverse mAbs provide a powerful toolkit to dissect the role of DNA mismatch repair (MMR) proteins in HD.
INNOVATION SOLUTIONS
-
Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.
-
Curia’s in vivo Discovery Immunology team offers high-performance hybridoma-based technologies to help clients discover great antibodies that make a difference.
-
Curia offers phage and eukaryotic-based yeast display platforms for in vitro discovery and engineering of potent antibody candidates for therapeutic or diagnostic use. High-affinity functional antibodies are routinely selected against a wide range of conventional or challenging targets (e.g. GPCRs) using customized or in-licensed state-of-the-art libraries.
-
Curia has extensive experience with constructing and producing antibodies in our mammalian platforms.
-
Evaluating the developability of therapeutic drug candidates early can help circumvent potential issues in late-stage development.
-
Our collaborative approach, proven track record, and deep technical expertise enable us to efficiently advance promising candidates, reduce development risk, and help transform innovative ideas into successful therapeutic realities.
-
Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.
-
Make the most of your molecule with integrated antibody discovery, engineering, and production capabilities designed to accelerate lead identification and optimization.
-
The Antibody Center at Curia provides end-to-end services in antibody discovery, engineering, and development.
-
Our Biologics services provide comprehensive Molecular Biology services at facilities in California and Massachusetts, offering a variety of services.
-
Curia has decades of experience in recombinant protein production.
-
Whether you require a particular expertise or a complete, experienced integrated small molecule discovery team, Curia can provide a high-performance solution to help turn your vision into reality.
-
For more than 30 years Curia has been meeting the custom synthesis needs of our clients.
-
Integrated drug discovery greatly benefits programs by blending various scientific disciplines into a unified team focused on your project.